Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Amicus Therapeutics (FOLD) Other financing activities (2017)

Amicus Therapeutics filings provide 1 years of Other financing activities readings, the most recent being $23.1 million for Q4 2017.

On a quarterly basis, Other financing activities changed N/A to $23.1 million in Q4 2017 year-over-year; TTM through Sep 2018 was $23.1 million, a N/A change, with the full-year FY2017 number at $23.1 million, up 31.98% from a year prior.
Other financing activities hit $23.1 million in Q4 2017 for Amicus Therapeutics, up from $28000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $23.1 million in Q4 2017 to a low of $28000.0 in Q1 2017.